Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2013

01-08-2013 | Viewpoint

On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives

Author: Michel L Tremblay

Published in: Breast Cancer Research | Issue 4/2013

Login to get access

Abstract

The increasing importance of signal transducer and activator of transcription 3 (STAT3) expression in human cancers has led several laboratories to examine in detail the expression of one of its major negative regulators in oncogenesis - the T-cell protein tyrosine phosphatase, nonreceptor type 2 (PTPN2). A recent paper by Shields and colleagues points to the associate depletion of PTPN2 in STAT3-positive breast cancers. We examine these findings and reflect on the mechanism of action of PTPN2 and the consequences of its modulation for STAT3 downstream signaling.
Literature
1.
Landis MD, Lehmann BD, Pietenpol JA, Chang JC: Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res. 2013, 15: 201-10.1186/bcr3355.CrossRefPubMedPubMedCentral
2.
Sonnenblick A, Uziely B, Nechushtan H, Kadouri L, Galun E, Axelrod JH, Katz D, Daum H, Hamburger T, Maly B, Allweis TM, Peretz T: Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2013, 138: 407-413. 10.1007/s10549-013-2453-x.CrossRefPubMed
3.
4.
St-Pierre J, Tremblay ML: Modulation of leptin resistance by protein tyrosine phosphatases. Cell Metab. 2012, 15: 292-297. 10.1016/j.cmet.2012.02.004.CrossRefPubMed
5.
ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, Shuai K: Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol. 2002, 22: 5662-5668. 10.1128/MCB.22.16.5662-5668.2002.CrossRefPubMedPubMedCentral
6.
Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, Van Roosbroeck K, Ferrando AA, Langerak AW, Meijerink JP, Sigaux F, Haferlach T, Wlodarska I, Vandenberghe P, Soulier J, Cools J: Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet. 2010, 42: 530-535. 10.1038/ng.587.CrossRefPubMedPubMedCentral
7.
Shields BJ, Wiede F, Gurzov EN, Wee K, Hauser C, Zhu HJ, Molloy TJ, O'Toole SA, Daly RJ, Sutherland RL, Mitchell CA, McLean CA, Tiganis T: TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. Mol Cell Biol. 2013, 33: 557-570. 10.1128/MCB.01016-12.CrossRefPubMedPubMedCentral
8.
Baeg GH, Zhou R, Perrimon N: Genome-wide RNAi analysis of JAK/STAT signaling components in Drosophila. Genes Dev. 2005, 19: 1861-1870. 10.1101/gad.1320705.CrossRefPubMedPubMedCentral
9.
Hutchins AP, Diez D, Takahashi Y, Ahmad S, Jauch R, Tremblay ML, Miranda-Saavedra D: Distinct transcriptional regulatory modules underlie STAT3's cell type-independent and cell type-specific functions. Nucleic Acids Res. 2013, 41: 2155-2170. 10.1093/nar/gks1300.CrossRefPubMedPubMedCentral
Metadata
Title
On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives
Author
Michel L Tremblay
Publication date
01-08-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3437

Other articles of this Issue 4/2013

Breast Cancer Research 4/2013 Go to the issue

Review

Platelets, coagulation and fibrinolysis in breast cancer progression

Research article

Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort

Research article

PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer

Research article

Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells

Research article

MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer

Research article

Evidence for a multipotent mammary progenitor with pregnancy-specific activity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits